For intermediate pre-test risk patients with an inconclusive bronchoscopy, Percepta GSC can down-classify the risk of primary lung cancer to low with a 91% NPV to help avoid additional invasive procedures or up-classify the risk to high with a 65% PPV to inform next intervention steps3.
LINK TO STUDY
R E F E R E N C E S 3. Bhorade S et al. Accuracy of the Next Generation Percepta Genomic Sequencing Classifier (GSC) for the Diagnosis of Suspicious Indeterminant Pulmonary Nodules. Poster presented at: Second Conference of the AABIP; August 15-17, 2019; Denver, CO.
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080